Microecology and Immunity in Patients With Anti-MDA5 Antibody Positive Dermatomyositis and Interstitial Lung Disease

The purpose of this study was to analyze the relationship between the microbial community, host immunity and the presence or absence of concurrent rapidly progressive interstitial lung disease patients with anti-MDA5 antibody positive dermatomyositis.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Microbiome Anti-MDA5 Antibody Positive Dermatomyositis Immune Function

Age range

18 year–100 year

Sex eligibility

All sexes

Study type

Observational

Primary location

PLA

Beijing, Beijing Municipality, 100853, China

Location status: Recruiting

Location contact

Zhimei Duan, doctor

CONTACT

[email protected]

13716376758

About this study

Methods: Bronchoalveolar lavage specimens of patients with anti-MDA5 antibody positive dermatomyositis and interstitial lung disease were collected and studied to analyze the relationship between the composition of patients' microecology and the occurrence and development of disease.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients who meet the diagnostic criteria of dermatomyositis and anti-MDA 5 antibody positive.
Anti-MDA5 antibody positive DM patients with RPILD meet the diagnostic criteria for RPILD.
Must have undergone bronchoalveolar lavage.
Age≥18 years old.
Patients who signed informed consent forms

Exclusion criteria

Patients who had other connective tissue diseases.
Patients with ILD or RPILD caused by infection, tumors, drugs, biochemistry and other factors.
Pregnant or lactating patients.
The patient also participated in any other clinical trial.
Disagreement for inclusion in this study

Treatment and study plan

Primary outcomes

The relationship between the microbial community and the presence or absence of interstitial lung disease

Time frame: 6 months

The relationship between the microbial community and the presence or absence of interstitial lung disease

Study contacts

Contact information is provided by the study sponsor or research team.

Zhimei Duan, doctor

CONTACT

[email protected]

13716376758

Sponsors and collaborators

Lead sponsor

Chinese PLA General Hospital

Other

Registry information

Official study title

Microecology and Host Immunity in Patients With Anti-melanoma Differentiation Associated Gene 5 Antibody Positive Dermatomyositis and Interstitial Lung Disease

Important dates

Study start: 2024
Primary completion: 2025
Study completion: 2026
First posted: Jan 12, 2024
Registry last updated: Jan 12, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed